Skip to main content
. 2017 Jan 29;8(9):14462–14478. doi: 10.18632/oncotarget.14895

Figure 3. RPL5 is a clinically relevant candidate tumor suppressor in GBM.

Figure 3

Kaplan–Meier analysis of the effect of RPL5 expression on overall survival. Cases were divided in RPL5 low or high expressers according to whether expression was below or above median and survival was compared using the log-rank test. (A) GBM TCGA dataset; (B) SKCM TCGA dataset; (C) BRCA TCGA dataset; (D) Non-TCGA BRCA dataset available on the R2 platform (GEO accession: GSE1456).